Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice

Nature

Volumn 434, Issue 7034, 2005, Pages 782-786

  Steffens, Sabine ^a   Veillard, Niels R ^a   Arnaud, Claire ^a   Pelli, Graziano ^a   Burger, Fabienne ^a   Staub, Christian ^c   Zimmer, Andreas ^d   Frossard, Jean Louis ^b   Mach, François ^a  

^a Department of Medicine University Hospital Faculty of Medicine ^*  (Switzerland)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL ENGINEERING; CELLS; PATIENT TREATMENT; PULMONARY DISEASES;

ATHEROSCLEROSIS; CHRONIC INFLAMMATORY DISEASE; DELTA-9-TETRAHYDROCANNABINOL (THC); LOW DOSE ORAL CANNABINOID THERAPY;

RESPIRATORY THERAPY;

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; APOLIPOPROTEIN E; CANNABINOID; CANNABINOID 2 RECEPTOR; DRONABINOL; GAMMA INTERFERON; CHEMOKINE RECEPTOR; MESSENGER RNA; MONOCYTE CHEMOATTRACTANT PROTEIN 1 RECEPTOR; TETRAHYDROCANNABINOL; THIOGLYCOLIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BONE MARROW CELL; CELL ISOLATION; CELL PROLIFERATION; CHEMOTAXIS; CHRONIC INFLAMMATION; CONTROLLED STUDY; CULTURAL ANTHROPOLOGY; CYTOKINE RELEASE; DRUG EFFICACY; GENE EXPRESSION; HEART DISEASE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VITRO STUDY; KNOCKOUT MOUSE; LOW DRUG DOSE; LYMPHOID CELL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME; ANIMAL; ARTERIOSCLEROSIS; CELL CULTURE; CYTOLOGY; DISEASE COURSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOUSE MUTANT; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; SECRETION; SURVIVAL RATE; TH1 CELL;

MURINAE;

ANIMALS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; INFLAMMATION; INTERFERON TYPE II; MACROPHAGES; MICE; MICE, KNOCKOUT; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CHEMOKINE; RNA, MESSENGER; SURVIVAL RATE; TETRAHYDROCANNABINOL; TH1 CELLS; THIOGLYCOLATES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17144400758     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature03389     Document Type: Article

References (30)

1. Libby, P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002).
2. Klein, T. W. et al. The cannabinoid system and immune modulation. J. Leukoc. Biol. 74, 486-496 (2003).
3. Buckley, N. E. et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol. 396, 141-149 (2000).
4. Rinaldi-Carmona, M. et al. SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284, 644-650 (1998).
5. Libby, P., Ridker, P. M. & Maseri, A. Inflammation and atherosclerosis. Circulation 105, 1135-1143 (2002).
6. Mach, F. Statins as immunomodulatory agents. Circulation 109 (suppl.), II15-II17 (2004).
7. Srivastava, M. D., Srivastava, B. I. & Brouhard, B. D9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40, 179-185 (1998).
8. Zhu, L. X. et al. Δ-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J. Immunol. 165, 373-380 (2000).
9. 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J. Neuroimmunol. 133, 124-131 (2002).
10. 9-Tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. 23, 73-81 (1989).
11. Malfait, A. M. et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA 97, 9561-9566 (2000).
12. Sulcova, E., Mechoulam, R. & Fride, E. Biphasic effects of anandamide. Pharmacol. Biochem. Behav. 59, 347-352 (1998).
13. Brenneisen, R., Egli, A., Elsohly, M. A., Henn, V. & Spiess, Y. The effect of orally and rectally administered Δ9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int. J. Clin. Pharmacol. Ther. 34, 446-452 (1996).
14. 9- tetrahydrocannabinol in man on mood and performance measures: a dose-response study. Pharmacol. Biochem. Behav. 35, 861-864 (1990).
15. Lichtman, A. H., Poklis, J. L., Poklis, A.,Wilson,D. M. & Martin, B. R. The pharmacological activity of inhalation exposure to marijuana smoke in mice. Drug Alcohol Depend. 63, 107-116 (2001).
16. 9-THC on spatial reference and working memory in mice. Psychopharmacology (Berl.) 157, 142-150 (2001).
17. Nakashima, Y., Plump, A. S., Raines, E. W., Breslow, J. L. & Ross, R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14, 133-140 (1994).
18. Reddick, R. L., Zhang, S. H. & Maeda, N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb. 14, 141-147 (1994).
19. Tangirala, R. K., Rubin, E. M. & Palinski, W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid Res. 36, 2320-2328 (1995).
20. Johnson, Z. et al. Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J. Immunol. 173, 5776-5785 (2004).
21. Daugherty, A. & Rateri, D. L. T lymphocytes in atherosclerosis: the yin-yang of Th1 and Th2 influence on lesion formation. Circ. Res. 90, 1039-1040 (2002).
22. Moeller, F. & Nielsen, L. B. Aortic recruitment of blood lymphocytes is most pronounced in early stages of lesion formation in apolipoprotein-E- deficient mice. Atherosclerosis 168, 49-56 (2003).
23. Song, L., Leung, C. & Schindler, C. Lymphocytes are important in early atherosclerosis. J. Clin. Invest. 108, 251-259 (2001).
24. Benagiano, M. et al. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc. Natl Acad. Sci. USA 100, 6658-6663 (2003).
25. Laurat, E. et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 104, 197-202 (2001).
26. Mulhaupt, F. et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc. Res. 59, 755-766 (2003).
27. Kwak, B. R. et al. Reduced connexin43 expression inhibits atherosclerotic lesion formation in lowdensity lipoprotein receptor-deficient mice. Circulation 107, 1033-1039 (2003).
28. 9-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. Forensic Sci. Int. 123, 159-164 (2001).
29. Hickey, M. J., Bullard, D. C., Issekutz, A. & James, W. G. Leukocyte-endothelial cell interactions are enhanced in dermal postcapillary venules of MRL/fas(lpr) (lupus-prone) mice: roles of P- and E-selectin. J. Immunol. 168, 4728-4736 (2002).
30. Veillard, N. R., Steffens, S., Burger, F., Pelli, G. & Mach, F. Differential expression patterns of proinflammatory and antiinflammatory mediators during atherogenesis in mice. Arterioscler. Thromb. Vasc. Biol. 24, 2339-2344 (2004).